Pharma Pulse: A call for U.K. Pricing Reform and the Latest FDA-Approved Biosimilar for Bone Health

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access and healthcare innovation. I’m your host, and let’s get into today’s headlines.

• First, Eli Lilly is pressing the U.K. government to overhaul its drug pricing framework, warning that future investment in the country depends on higher medicine prices and reforms to an industry rebate system they describe as financially unsustainable. Lilly’s international business president Patrik Jonsson stated that U.K. medicine prices have been "far too low for far too long," and suggested innovative outcomes-based models for obesity therapies that tie reimbursement to measurable patient improvements.
• Next, the FDA has approved denosumab-adet, known as Ponlimsi, as a biosimilar to Prolia for all indications, including the treatment of postmenopausal women with osteoporosis at high risk for fracture. Developed by Teva, this subcutaneous injection maintains a similar profile of efficacy and safety to the reference product, though it carries a boxed warning regarding the risk of severe hypocalcemia in patients with advanced chronic kidney disease.

That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.